FDA approves Abbvie's hep c treatment

The Food and Drug Administration on Thursday approved Abbvie's hepatitis C treatment Mavyret.

Mavyret is intended to treat adults with all types of chronic hepatitis C virus with mild or no cirrhosis who have not previously received treatment for the illness. Patients with moderate to severe kidney disease, individuals on dialysis and genotype 1 patients unsuccessfully treated with a different drug are also eligible for treatment.

Mavyret represents the first drug for all hepatitis C genotypes with an eight-week treatment duration. Previously, the standard treatment length for the disease was at least 12 weeks.

More articles on supply chain:

4 latest FDA approvals
Senate passes FDA user fee reauthorization bill
How retail pharmacies are driving down generic drug prices: 3 things to know

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Whitepapers

Featured Webinars